Eli Lilly’s Foundayo Pill Poised to Shake Up $100B Obesity Drug Market
In a move set to reshape the competitive landscape of obesity treatment, the U.S. Food and Drug Administration has granted approval to Eli Lilly’s once-daily oral GLP-1 agonist, Foundayo. This landmark decision not only cements Foundayo’s place as the second FDA-sanctioned oral obesity pill but also positions it as a direct challenger to Novo Nordisk’s oral formulation of Wegovy. With analysts forecasting the global GLP-1 market to exceed $100 billion by 2030, the stakes—and potential—are immense.
Key Takeaways:
- FDA approves Eli Lilly’s Foundayo, a once-daily oral GLP-1 agonist for obesity.
- Foundayo becomes the second FDA-approved oral obesity pill, intensifying competition with Novo Nordisk’s Wegovy.
- The GLP-1 drug market is projected to surpass $100 billion globally by 2030.
- Oral formulations are expected to drive broader adoption and market growth.
🚀 Stay Ahead of the Curve!
Follow the source for instant updates.
Top comments (0)